Evidence map›Paper›PMID 41246724›Full record

ArticleCureus2025

Seizure Following Zolpidem Withdrawal in a Patient Presenting as a Stroke Lysis Call: A Case Report.

Hadi Chishti, Eoin Melby, Zainab Mansoor

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hadi ChishtiInternal Medicine, Ulster Hospital, Belfast, GBR.
Eoin MelbyMedicine, Ulster Hospital, Belfast, GBR.
Zainab MansoorInternal Medicine, Ulster Hospital, Belfast, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke lysis, or thrombolysis, is a time-sensitive intervention for acute ischemic stroke, but careful distinction from stroke mimics is essential to avoid inappropriate treatment. Zolpidem, a non-benzodiazepine hypnotic, is generally regarded as having low dependence potential; however, prolonged or high-dose use can result in withdrawal syndromes, including seizures. We report the case of a 46-year-old woman presenting with acute left upper limb weakness and facial sensory changes, initially managed as a stroke lysis call. She was outside the lysis window and had initial negative neuroimaging. Within 24 hours, she developed recurrent generalized seizures requiring intravenous lorazepam. Subsequent collateral history revealed chronic high-dose zolpidem use (50-200 mg daily), discontinued abruptly, confirming a diagnosis of zolpidem withdrawal seizure. The patient was successfully treated with a benzodiazepine taper and discharged with community mental health and substance misuse follow-up. This case emphasizes the importance of thorough medication history-taking in stroke evaluations, as withdrawal syndromes can closely mimic acute cerebrovascular events. It is also interesting to note that zolpidem can increase the risk of strokes.

Indexed as

acute stroke mimicgamma-aminobutyric acidseizuresstrokesubstance-related disorderszolpidem

Identifiers

PMID41246724
PMCPMC12618947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.